Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors

Area of Science:

• Immunology
• Pharmacology
• Respiratory Medicine

Background:

• Eosinophil accumulation in lung tissue is a key feature of asthma.
• Prostaglandin E2 (PGE2) has anti-inflammatory effects in asthma, but mechanisms are unclear.

Purpose of the Study:

• To investigate the role of PGE2 and its receptors in eosinophil chemotaxis and activation.
• To explore the therapeutic potential of EP2 receptor agonists in eosinophilic diseases.

Main Methods:

• Studied the effect of PGE2 and EP2 agonists/antagonists on purified human eosinophil migration and degranulation.
• Utilized animal models (guinea pig, mice) to assess in vivo effects on eosinophil mobilization and accumulation.
• Examined EP2 receptor expression in human and murine tissues using immunostaining.

Main Results:

• PGE2 and the EP2 agonist butaprost potently inhibited eosinophil chemotaxis and C5a-induced degranulation.
• Inhibition of eosinophil migration by PGE2 involved PI3K and protein kinase C activation.
• EP2 agonist butaprost reduced eosinophil mobilization from bone marrow and allergen-induced lung accumulation in mice.
• Human eosinophils express EP2 receptors, which are also found in murine airway epithelium and infiltrating leukocytes.

Conclusions:

• EP2 receptor agonists effectively inhibit eosinophil trafficking and activation.
• EP2 receptor agonists represent a promising therapeutic strategy for eosinophilic diseases.